DALLAS, TX, March 24, 2016—The selection phase for the unprecedented opportunity to significantly reduce the devastating global burden of coronary heart disease through the One Brave Idea™ research fund is underway. During the one month application period (January 14-February 14), hundreds of applications were received for One Brave Idea™ from people around the world. The Joint Leadership Group representing the funding organizations has convened and selected 26 applicants that will proceed to the next round of review. From there, the Joint Leadership Group will further narrow down the applicants for in-person interviews with the goal of final selection occurring this summer.

Illustrating innovative new approaches for scientific discovery, the American Heart Association (AHA), Verily (formerly Google Life Sciences) and AstraZeneca have committed a total of $75 million over at least five years towards supporting the One Brave Idea™ research fund to find the leader, team, and idea to end coronary heart disease and its consequences. The selected leader and their team will have resources beyond the financial investment of the organizations by combining the AHA's medical and scientific expertise, Verily's technical prowess, and scientific insights and mentoring from AstraZeneca.

“We are very pleased with the wealth of scientific ideas, the diversity and synergies of the applicants and the concepts we received from hundreds of submissions representing 22 different countries,” said Nancy Brown, CEO of the American Heart Association and a Joint Leadership Group member. “This is an incredible time for research. Together, we are unleashing the true power of science and innovation.”

This bold approach is the single largest research one-time investment in the fight to end coronary heart disease and its consequences. The investments from Verily and AstraZeneca are the two largest ever received by the AHA in its 90 year history. The AHA remains steadfast in its commitment to its existing research programs and early investigators. This fund has been created over and above the AHA’s existing and ongoing commitments. Only submissions made through onebraveidea.com prior to the February 14th deadline are in consideration.


Media Inquiries:

American Heart Association

Jennifer Pratt, 716-432-3307, Jennifer.pratt@heart.org

Members of the One Brave Idea™ Joint Leadership Group:

Nancy Brown, CEO, American Heart Association; Robert Harrington, MD, Stanford University and AHA Board member; Joseph Loscalzo, MD PhD, Brigham and Women’s Hospital/Harvard Medical School and Chairman of the AHA’s Institute for Precision Cardiovascular Medicine; Andrew Conrad, PhD,  Chief Executive Officer, Verily; Jessica Mega, MD, MPH, Chief Medical Officer, Verily; Michael V. McConnell, MD, MSEE, Head, Cardiovascular Health Innovations, Verily; Gregory Keenan, MD, Vice President & Head of US Medical Affairs, AstraZeneca; Bruce Cooper, MD, Vice President & Head of Global Medical Affairs, AstraZeneca

About the American Heart Association

The American Heart Association is devoted to saving people from heart disease and stroke – America’s No. 1 and No. 5 killers. We team with millions of volunteers to fund innovative research, fight for stronger public health policies, and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.

About Verily

Verily, formerly Google Life Sciences, is focused on helping to move healthcare from reactive to proactive. Combining expertise from the fields of biology, chemistry, physics, medicine, electrical engineering and computer science, we’re developing new technology tools for physicians that can integrate easily into daily life and help transform the detection, prevention, and management of disease.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca-us.com